- Home
- TRIP vs KNSA Comparison
TRIP vs KNSA Comparison
Compare TRIP & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- KNSA
- Stock Information
- Founded
- TRIP 2000
- KNSA 2015
- Country
- TRIP United States
- KNSA United Kingdom
- Employees
- TRIP N/A
- KNSA N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- TRIP Technology
- KNSA Health Care
- Exchange
- TRIP Nasdaq
- KNSA Nasdaq
- Market Cap
- TRIP 1.6B
- KNSA 1.5B
- IPO Year
- TRIP 2011
- KNSA 2018
- Fundamental
- Price
- TRIP $11.72
- KNSA $20.21
- Analyst Decision
- TRIP Hold
- KNSA Strong Buy
- Analyst Count
- TRIP 14
- KNSA 6
- Target Price
- TRIP $17.57
- KNSA $37.17
- AVG Volume (30 Days)
- TRIP 2.8M
- KNSA 638.0K
- Earning Date
- TRIP 05-07-2025
- KNSA 04-29-2025
- Dividend Yield
- TRIP N/A
- KNSA N/A
- EPS Growth
- TRIP N/A
- KNSA N/A
- EPS
- TRIP 0.04
- KNSA N/A
- Revenue
- TRIP $1,835,000,000.00
- KNSA $423,239,000.00
- Revenue This Year
- TRIP $6.87
- KNSA $37.21
- Revenue Next Year
- TRIP $7.19
- KNSA $2.58
- P/E Ratio
- TRIP $329.05
- KNSA N/A
- Revenue Growth
- TRIP 2.63
- KNSA 56.60
- 52 Week Low
- TRIP $10.43
- KNSA $16.56
- 52 Week High
- TRIP $27.63
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- TRIP 38.37
- KNSA 44.56
- Support Level
- TRIP $10.43
- KNSA $18.26
- Resistance Level
- TRIP $11.95
- KNSA $21.24
- Average True Range (ATR)
- TRIP 0.85
- KNSA 1.12
- MACD
- TRIP -0.05
- KNSA -0.12
- Stochastic Oscillator
- TRIP 32.01
- KNSA 44.43
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.